Literature DB >> 29062359

Recovery from severe dysphagia in systemic sclerosis - myositis overlap: a case report.

Keith J Chinniah1, Girish M Mody1.   

Abstract

BACKGROUND: Dysphagia is common in inflammatory myopathies and usually responds to corticosteroids. Severe dysphagia requiring feeding by percutaneous endoscopic gastrostomy is associated with significant morbidity and high mortality. CLINICAL CASE: A 56-year old African Black woman initially presented with systemic sclerosis (SSC) - myositis overlap and interstitial lung disease. She responded to high dose corticosteroids and cyclophosphamide followed by azathioprine, with improvement in her lung function and regression of the skin changes. Six years later she had a myositis flare with severe dysphagia. Her myositis improved after high doses of corticosteroids, azathioprine and two doses of intravenous immunoglobulin (IVIG). As her dysphagia persisted, she was fed via a percutaneous endoscopic gastrostomy (PEG) tube and given a course of rituximab. Her dysphagia gradually resolved and the PEG tube was removed within two months. She received another dose of rituximab six months later and continued low dose prednisone and azathioprine. Her muscle power improved, weight returned to normal and she remained well 20 months after hospital discharge.
CONCLUSION: Our patient with SSC-myositis overlap and severe dysphagia requiring PEG feeding, improved with high dose corticosteroids, azathioprine, two courses of IVIG and rituximab, and remained in remission 20 months after hospital discharge.

Entities:  

Keywords:  Severe dysphagia; myositis overlap; systemic sclerosis

Mesh:

Substances:

Year:  2017        PMID: 29062359      PMCID: PMC5637048          DOI: 10.4314/ahs.v17i2.38

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  12 in total

1.  Percutaneous endoscopic gastrostomy feeding--a life-saving intervention in SSc-myositis overlap with pharyngeal dysfunction.

Authors:  Leena Das; Andrew Bowden; Robert G Cooper; William Mitchell; Margaret O'Sullivan; Ariane L Herrick
Journal:  Rheumatology (Oxford)       Date:  2012-03-29       Impact factor: 7.580

2.  Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients.

Authors:  I Marie; J-F Menard; P Y Hatron; E Hachulla; L Mouthon; K Tiev; P Ducrotte; P Cherin
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-12       Impact factor: 4.794

3.  Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry.

Authors:  Marion Couderc; Jacques-Eric Gottenberg; Xavier Mariette; Eric Hachulla; Jean Sibilia; Olivier Fain; Arnaud Hot; Maxime Dougados; Liana Euller-Ziegler; Pierre Bourgeois; Claire Larroche; Anne Tournadre; Zahir Amoura; Bernard Mazières; Philippe Arlet; Michel De Bandt; Thierry Schaeverbeke; Martin Soubrier
Journal:  Rheumatology (Oxford)       Date:  2011-10-22       Impact factor: 7.580

Review 4.  Inflammatory muscle diseases.

Authors:  Marinos C Dalakas
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245

5.  Rituximab treatment in patients with refractory inflammatory myopathies.

Authors:  Elien A M Mahler; Marlies Blom; Nicol C Voermans; Baziel G M van Engelen; Piet L C M van Riel; Madelon C Vonk
Journal:  Rheumatology (Oxford)       Date:  2011-05-13       Impact factor: 7.580

6.  Spontaneous skin regression and predictors of skin regression in Thai scleroderma patients.

Authors:  Chingching Foocharoen; Ajanee Mahakkanukrauh; Siraphop Suwannaroj; Ratanavadee Nanagara
Journal:  Clin Rheumatol       Date:  2011-04-12       Impact factor: 2.980

Review 7.  Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis.

Authors:  Patrick A Gordon; John B Winer; Jessica E Hoogendijk; Ernest H S Choy
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

Review 8.  Review article: the gastrointestinal complications of myositis.

Authors:  E C Ebert
Journal:  Aliment Pharmacol Ther       Date:  2009-11-03       Impact factor: 8.171

9.  Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.

Authors:  Chester V Oddis; Ann M Reed; Rohit Aggarwal; Lisa G Rider; Dana P Ascherman; Marc C Levesque; Richard J Barohn; Brian M Feldman; Michael O Harris-Love; Diane C Koontz; Noreen Fertig; Stephanie S Kelley; Sherrie L Pryber; Frederick W Miller; Howard E Rockette
Journal:  Arthritis Rheum       Date:  2013-02

10.  Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients.

Authors:  Terry H Oh; Kathlyn A Brumfield; Tanya L Hoskin; Kathryn A Stolp; Joseph A Murray; Jeffrey R Bassford
Journal:  Mayo Clin Proc       Date:  2007-04       Impact factor: 7.616

View more
  1 in total

Review 1.  Inflammatory myopathies overlapping with systemic sclerosis: a systematic review.

Authors:  Jucier Gonçalves Júnior; Naoki Mugii; Pleiades Tiharu Inaoka; Percival Degrava Sampaio-Barros; Samuel Katsuyuki Shinjo
Journal:  Clin Rheumatol       Date:  2022-02-27       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.